WSJ – Researchers Ready Lab-Grown Covid-19 Delta Variant for Human Trials

U.K. company is growing the highly contagious variant under tight lab controls for use in challenge studies Scientists have coaxed the Delta strain to mature, said Andrew Catchpole, chief scientiic oficer of trial partner hVivo. PHOTO: HVIVO SERVICES LIMITED by Jenny Strasburg – Wall Street Journal LONDON—While the rest of the world is trying to […]

The Times – Drug Tester’s £8m Contract Win

Tom Howard Market Report – Open Orphan #ORPH shares rose after the AIM company bagged a new contract worth £8.1m with one of Europe’s biggest drugmakers… Link here to read the full Times article

Open Orphan #ORPH – £8.1m Asthma Human Challenge Study Contract Win

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed an £8.1m contract with a major global pharmaceutical company to test its inhaled human rhinovirus (hRV) antiviral product using […]

Open Orphan #ORPH – Development of Controlled Human Malaria Infection Human Challenge Study

Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in testing vaccines and antivirals using human challenge clinical trials, announces that its subsidiary, hVIVO, has developed a Controlled Human Malaria Infection (“CHMI”) challenge model, both strengthening and further diversifying the Company’s world leading portfolio of viral challenge study models. […]

Open Orphan #ORPH – Pfizer successful Phase 2a human challenge trial

Rapid progress at Open Orphan #ORPH. In Pfizer’s recent quarterly update, CEO Albert Bourla, noted (on page 5) that one of the key highlights of Pfizer’s Q2 was the “Successful Phase 2a human challenge trial with RSV Adult vaccine candidate”. Although Pfizer have not mentioned Open Orphan by name and we have not formally announced […]

Open Orphan #ORPH – DNDi Phase II trial to support river blindness drug

Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) which is the world leader in testing vaccines and antivirals using human challenge clinical trials, announces a contract to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness. Venn Life Sciences […]

Open Orphan PLC #ORPH – NEJM Opinion Piece

The New England Journal of Medicine (NEJM) publishes editorial relating to Human Challenge Programme Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that an editorial opinion piece regarding the UK Government’s Human Challenge Programme has been published in the latest edition […]